AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00936221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
Study NCT00936221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dacarbazine
Description: 1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
Study NCT00936221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03034213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gentrix™ Surgical Matrix (Treatment)
Description: Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
Study NCT03034213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)
Description: A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
Study NCT02921373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19F Cell Sense-labeled PBMC
Description: Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging.
Study NCT02921373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
Study NCT03954457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-CWS
Description: The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
Study NCT03954457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
Study NCT00758160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate
Description: Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
Study NCT00715663 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
Study NCT02712593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen™ 100
Study NCT02712593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen™ 300
Study NCT02712593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen™ 1000
Study NCT02712593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00687336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Empirical Hp eradication
Description: Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
Study NCT00687336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eradication treatment guided by a positive test
Description: Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
Study NCT02265081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: pelvic floor ultrasound
Study NCT02265081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: pelvic floor ultrasound
Study NCT02265081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uroflow-meter
Description: uroflow meter: measurement of passed urine volume
Study NCT02265081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uroflow-meter
Description: uroflow meter: measurement of passed urine volume
Study NCT05075343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom foot orthoses
Description: 3D printed custom foot orthoses (CFO) were designed by the same experimented podiatrist based on a detailed clinical and biomechanical examination and a 3D foot scan obtained for each participant. The degrees and types were adjusted at the CFO delivery according to each patient's comfort and tolerance.~The intervention period was 7weeks. The participants were taught to wear the CFO progressively during the first two weeks to allow for the lower limbs' muscles and structures to adjust to the CFO, and to wear the orthoses for the next 5 weeks, 7 days a week as often as they could.
Study NCT05351645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope.
Study NCT02691351 — intervention group
Intervention type: OTHER
Intervention: Prospective Registry
Description: Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~1. Regimen~2. Response Evaluation~3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection
Study NCT00624663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
Study NCT00624663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine
Description: Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
Study NCT02238197 — intervention group
Intervention type: DRUG
Intervention: Atrovent® Inhalation Solution
Study NCT03792217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.3% NaOCl
Description: Endodontic irrigant
Study NCT03792217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5.25% NaOCl
Description: Endodontic irrigant
Study NCT01696318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support for the Family Health Team
Description: Participation in physical educator, dietitian and pharmacist in primary health care
Study NCT02781896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pacing catheter
Description: Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
Study NCT02781896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: valve delivery guidewire
Description: Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
Study NCT02186509 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy
Description: Undergo hyperfractionated radiation therapy
Study NCT02186509 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT02186509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT02186509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT01463293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. lactis HN019
Description: Capsule containing 10 billion cfu B. lactis HN019 once a day
Study NCT01463293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. lactis HN019
Description: Capsule containing 1 billion cfu B. lactis HN019 once a day
Study NCT01463293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing no probiotic once a day
Study NCT01949597 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic surgery for deep endometriosis
Study NCT02554630 — intervention group
Intervention type: OTHER
Intervention: Adjuvant
Description: Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
Study NCT02554630 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Description: Blood collection will be performed on all groups.
Study NCT00210119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glivec
Study NCT03184090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: palbociclib in combination with endocrine therapy (investigator's choice)
Study NCT03184090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (non IMP)
Description: Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
Study NCT06628752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulation through a device implanted bilaterally into deep brain structures.
Study NCT06628752 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulation through a device implanted bilaterally into deep brain structures.
Study NCT04712591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Auditory stimuli
Description: Auditory stimuli (passive, active perturbations)
Study NCT03374930 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multiple rapid swallows test
Description: Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
Study NCT04450784 — intervention group
Intervention type: OTHER
Intervention: collection of the clinical and biological characteristics of secondary AMLs in children
Description: to record scientific and medical information on cases of secondary Acute Myeloid Leukemias that have occurred in France since 2013
Study NCT02086084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Standard care
Study NCT02086084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Standard care
Study NCT02086084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R
Description: Application of ECCO2R in addition to NIV
Study NCT03598920 — intervention group
Intervention type: DEVICE
Intervention: AsspireAssist
Description: Endoscopic bariatric procedure using the AsspireAssist device
Study NCT03598920 — intervention group
Intervention type: OTHER
Intervention: Nutritional consulting
Description: Nutritional consulting provided by a specialized consultant.
Study NCT02774122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAABT
Description: CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
Study NCT02774122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: masking therapy
Description: Masking intervention was a standard monophone tinnitus masking therapy.
Study NCT01747889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic chest drainage system
Description: Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients
Study NCT01671072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C
Description: TissueGene-C at 1.8 x 10\^7 cells
Study NCT01671072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sodium chloride 0.9%, 3.5ml
Study NCT00662662 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
Study NCT02868567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalfampridine
Description: Pill open label
Study NCT02860000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT02860000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT02860000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: growth factor
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: growth factor
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: R-CHOP
Description: immuno-chemotherapy
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy: R-CHOP
Description: immuno-chemotherapy
Study NCT02141568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical and Psychological treatment
Description: Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist).
Study NCT04090138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Setria performance blend
Description: Oral capsules
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy: R-DHAP
Description: immuno-chemotherapy
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: Dexa-BEAM
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cell harvest
Description: procedure
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell harvest
Description: procedure
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: radiation
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: radiation
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high-dose chemotherapy: Cyclophosphamide
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-dose chemotherapy: Ara-C /Melphalan
Description: chemotherapy
Study NCT04090138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study NCT04186702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INTRAVITREAL RANIBIZUMAB INJECTION
Description: interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
Study NCT00703794 — intervention group
Intervention type: DEVICE
Intervention: The AXIUM Progressive Coil System
Description: Embolization of aneurysm
Study NCT01978470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Trigeminal Nerve Stimulation (eTNS)
Description: External stimulation of the trigeminal nerve.
Study NCT00828074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
Study NCT00828074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
Study NCT02883075 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Supine position
Description: Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
Study NCT02883075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral position
Description: Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
Study NCT02883075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral position
Description: Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
Study NCT02572596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
Study NCT02572596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: CTX 2.5/m2 for 2 days.
Study NCT02572596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: CTX 2.5/m2 for 2 days.
Study NCT02572596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: -CSF
Description: 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
Study NCT02572596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: -CSF
Description: 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
Study NCT01264237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: 90mg Tablet QD at 10:00a.m.
Study NCT01264237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet QD at 10:00a.m.
Study NCT04064242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMK389
Description: single i.v. dose every 4 weeks
Study NCT02150083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OR retrograde fill
Study NCT04064242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single i.v. dose every 4 weeks